Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. The major developments are witnessed in immune therapies where breakthroughs will be appearing soon. The conference will address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.
Associate Director, Translational Biomarkers & Bioanalysis, UCB
Deputy Managing Director, University of Tübingen
Board Member, MarketsandMarkets
Chief Scientific Officer, Proteome Sciences PLC
Associate Director, Translational Biomarkers & Bioanalysis, UCB
Deputy Managing Director, University of Tübingen
Vice President, Quanterix
Director of the CRUK KHP Centre and Professor of Cancer Cell Biology, KCL
VP, Head Oncology Statistics and Data Management, Bayer AG
Professor of Molecular Oncology (Barts Cancer Institute), Queen Mary University of London (QMUL)
Professor of Cancer Cell Biology, University of Manchester
Scientist - Imaging Specialist, Roche
Director of Corporate and Business Development, Ultivue
Research Associate, University of Oxford
Radisson Blu Edwardian, Grafton Hotel, London
.jpg){kind=logo}
